Recipharm and the cancer drug development company Kancera have signed a contract for the development and manufacture of the pharmaceutical candidate KAND567. Kancera’s pharmaceutical candidate KAND567 works by blocking the Fractalkine system and has been shown in preclinical disease models to effectively counteract the onset of autoimmune disorders, as well as neuritis and pain in connection with chemotherapy against cancer. In future clinical studies, Kancera intends to treat patients with t...